Novasep teams up with AstraZeneca to produce COVID-19 vaccine for Europe

Novasep, viral vector producer, has signed a partnership with AstraZeneca for the production of the Oxford University COVID-19 vaccine. Novasep will produce the active substance of the vaccine in its Belgian facilities

The partnership follows the agreement between AstraZeneca and the Inclusive Alliance for Vaccines (IAV), to supply Oxford University’s COVID-19 vaccine to Europe in 2021.

Production will be carried out at Novasep’s Belgian site in Seneffe. Thanks to the biopharmaceutical ecosystem in the region, Novasep can also take advantage of additional human resources needed to achieve this project.

Michel Spagnol, President and CEO of Novasep said: “It is a great honour and pride for our teams in France and Belgium to contribute on a European scale to the fight against this pandemic. This confirms the increasing trends towards biopharmaceuticals and validates the strategic investment choices that we have been making in the production of viral vectors for several years with the support of our board. We thank AstraZeneca for its confidence in our expertise and industrial capacity. We look forward to meeting one of the major challenges of this decade”.

Image credit: CDC

 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free